Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.
Androgen ablation therapy is currently the primary treatment for metastatic prostate cancer. Unfortunately, in nearly all cases, androgen ablation fails to permanently arrest cancer progression. As androgens like testosterone are withdrawn, prostate cancer cells lose their androgen sensitivity and b...
Main Authors: | Ryan Tasseff, Satyaprakash Nayak, Saniya Salim, Poorvi Kaushik, Noreen Rizvi, Jeffrey D Varner |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2812491?pdf=render |
Similar Items
-
A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials.
by: Satyaprakash Nayak, et al.
Published: (2008-04-01) -
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01) -
Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
by: Simeng Wen, et al.
Published: (2020-07-01) -
Mechanism of anti-cancer activity of curcumin on androgen-dependent and androgen-independent prostate cancer
by: Abd. Wahab, Nurul Azwa, et al.
Published: (2020) -
Anticancer imidazoacridinone C-1311 is effective in androgen-dependent and androgen-independent prostate cancer cells
by: Niemira, M, et al.
Published: (2020)